Nalaganje...

Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease

Monoclonal antibodies to tumor necrosis factor (TNF) have become a mainstay of the therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years. Although highly effective, primary and secondary nonresponse are common and associated with poor clinical outcomes and significant...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Therap Adv Gastroenterol
Main Authors: Kopylov, Uri, Seidman, Ernest
Format: Artigo
Jezik:Inglês
Izdano: SAGE Publications 2016
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4913332/
https://ncbi.nlm.nih.gov/pubmed/27366220
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X16638833
Oznake: Označite
Brez oznak, prvi označite!